India: MOU Agilent Collaborates with IIT Delhi to Promote Biopharmaceutical Research
Agilent will be funding an incubator site at the Indian Institute of Technology Delhi with an aim to enhance the quality and safety of biotherapeutics. The move will also support and offer training to researchers on protein characterisation.
California/USA – Agilent Technologies has recently announced that it is joining forces with the Indian Institute of Technology Delhi (IIT Delhi) to promote biopharmaceutical research.
Agilent and IIT Delhi signed a memorandum of understanding under which Agilent is contributing funds to support the incubator at IIT New Delhi. The move will support researchers at the institute to establish global best practices for identifying and characterising biopharmaceuticals. The research conducted by IIT Delhi examines and reports on the quality of biotherapeutic products for the Indian market.
Visiting the IIT Delhi campus, Agilent CEO, Mike Mc Mullen, spoke about Agilent’s history of innovation, focus on research and academia, and vision for the future. Likewise, the institute’s Director, Prof. V. Ramgopal Rao, spoke about the institute’s mission and role in promoting collaborations between academia and the industry.
Agilent will be contributing funds to the IIT Delhi incubator site, as a part of its corporate social responsibility initiative, with the goal of enhancing the quality and safety of biotherapeutics. The aim is to offer world-class training to researchers from academia and the industry on protein characterisation.
The setup will be under the DBT Center of Excellence for Biopharmaceutical Technology (CBT) and will support incubated startups at IIT Delhi performing protein analysis. This will prove beneficial for providing critical information to policy makers for ensuring safe and efficacious biotherapeutic products in India.
“We are happy to be associated with Agilent,” said Prof. Anurag S. Rathore (IIT Delhi), Coordinator of the CBT. “Agilent’s broad range of technologies will further boost our efforts at the Centre of Excellence for Biopharmaceutical Technology. This mutually constructive and productive partnership will hopefully lead to promising results for the entire biotherapeutics ecosystem.”
“We are excited to embark on this initiative with IIT Delhi, an institute with the country’s brightest minds engaged in research and technology,” said Bharat Bhardwaj, country general manager, Agilent India. “Agilent’s relationship with IIT Delhi goes back decades. The new memorandum of understanding that we have signed will further strengthen our relationship and will enhance the ability to do cutting-edge research, which can be used to improve the quality of life for the community at large, through the application of new innovations.”